Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature.

Abstract

Implant-related infections may need suppressive antibiotic therapy (SAT). We describe a SAT strategy using dalbavancin with therapeutic drug monitoring (TDM). This is a retrospective bicentric study of patients with implant-related infection who received dalbavancin SAT between January 2021 and September 2023. Fifteen patients were included. Median number of injections was 4 (IQR: 2-7). Median time between two reinjections was 57days (IQR 28-82). Dalbavancin plasma concentrations were above 4mg/L for 97.9% of dosages (93/95) and above 8mg/L for 85% (81/95). These results support the use of dalbavancin SAT for implant-related infections.